Mind Medicine Australia has secured a supply agreement with Optimi Health for MDMA and psilocybin.
This agreement will ensure Australian psychiatrists and researchers have affordable access to GMP grade medicines for clinical trials and the TGA’s Authorised Prescriber Scheme, which begins from July 1st 2023.
Read Optimi Health’s press release for more details here.
Additionally, we are able to supply MDMA and psilocybin at no cost for innovative clinical trials.
Registered health professionals and researchers are invited to fill out the EOI form below, and a member of our team will reach out to provide further details.